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Abstract
Objectives Individual activities of N-acetyltransferase 2
(NAT2) and of xanthine oxidase (XO) can be assessed using
ratios of urinary caffeine metabolites. We investigated how
ratios changed over time and which urine collection interval
would be the best for NAT2 and XO activity assessments.
Methods On two occasions separated by 14 days, 16
healthy male Caucasians collected urine before and 0–2,
2–4, 4–6, 6–8, 8–12, 12–16 and 16–24 h after a dose of 150mg
caffeine given in the framework of a phenotyping cocktail
study. The metabolites 5-acetylamino-6-formylamino-3-
methyluracil (AFMU), 5-acetylamino-6-amino-3-methyluracil
(AAMU), 1-methylxanthine (1X), and 1-methylurate (1U)
were quantified with LC-MS/MS. The molar ratio (AFMU+
AAMU)/(1X+1U+AFMU+AAMU) was used as a NAT2
metric, while the ratio 1U/(1X+1U) served as XO metric.
Results The NAT2 ratios were stable in the intervals 4–
24 h after caffeine dosing. Mean intra-individual coeffi-
cients of variation were 11–23% starting 4 h post-dose,
while inter-individual variability reached 37–75%. The XO
ratios increased gradually by 14% from the 2–4 to the 16–
24 h interval. The mean intra- and inter-individual
coefficients of variation of XO activity were 3–18 and 7–
10% respectively. No significant differences between study
occasions were observed.
Conclusions Any sampling interval at least 4 h after
caffeine dosing is suitable for NAT2 and XO activity
assessments. XO activities can only be compared between
volunteers and studies if the same urine collection schedule
has been respected. The low intraindividual variability
allows for sample sizes of 16 and 6 participants in
crossover interaction studies of NAT2 and XO activity
respectively.
Keywords N-acetyltransferase 2 . Xanthine oxidase .
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Introduction
The genetically polymorphic phase-II enzyme N-acetyl-
transferase type 2 (NAT2) is important for the metabolism
of drugs such as isoniazid and several sulfonamides and is
involved in the bioactivation of several procarcinogens, e.g.
from tobacco smoke [1]. More than 50 allelic variants have
been described, and approximately 50% of Caucasians are
classified as slow acetylators.
The enzyme xanthine oxidase (XO) plays a crucial role
in many metabolic processes: it produces reactive oxygen
species, catalyses uric acid production and plays a role in
the elimination of thiopurine drugs [2–4]. About 20 genetic
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variants are known [5], but in studies, 4% or less of
volunteers examined showed decreased enzyme activity [6].
However, xanthine oxidase activity is also influenced by
endogenous compounds, other drugs (e.g. inhibition by the
allopurinol metabolite oxypurinol or induction by cytokines
or ethacrynic acid) and environmental factors [2, 3].
Since the 1980s, the quantification of urinary caffeine
metabolites has been used frequently to assess the actual
activities of NAT2 [7, 8] and XO [9]. A variety of different
metabolite ratios, sampling schemes and schedules have
been developed and are used in different study settings. Not
every approach has been fully validated, so the results may
not always be reliable and comparable. Generally, NAT2
activity assessment has attracted more attention than XO
activity estimation. It is therefore important to know
whether differences in the phenotyping procedures have a
relevant effect on the results and reduce their comparability.
In this context, we showed earlier that caffeine from
uncontrolled dietary sources may be used for NAT2
phenotyping if a correct abstinence period is respected
[10]. The present work was carried out to investigate
whether the timing of urine collections, which differs
considerably across publications, has a relevant influence
on NAT2 and XO phenotype assessments, and whether
intra- and inter-individual variability changes as a function
of (urine collection) time. Since intra-individual variability
is a crucial factor for the correct estimation of sample sizes
in crossover interaction studies, we determined the numbers
of participants necessary for the reliable estimation of
changes in NAT2 and XO activities in such a study setting.
Methods
Study conduct and subjects
This investigation is based on urine samples collected
during a two-period, randomised crossover interaction
study in 16 healthy, young, non-smoking male Caucasians.
The study was carried out to assess the effects of
propiverine on the activities of hepatic CYP3A (using
intravenous midazolam), intestinal CYP3A (oral midazolam),
CYP2C9 (tolbutamide), CYP2C19 (mephenytoin), and
CYP1A2 (150 mg caffeine; Percoffedrinol tablets, Passauer,
Berlin, Germany) and which has been published earlier [11].
All volunteers gave their written informed consent
before the screening examination. The study was endorsed
by the Ethics Committee of the University of Cologne,
Germany, and conducted according to the principles of
good clinical practice and the laws of Germany.
The cocktail was given under controlled in-house
conditions on day 7 of regular administration of 15 mg
propiverine or placebo twice daily. A washout period of
14 days was respected between the two cocktail admin-
istrations. Any methylxanthine-containing food or beverage
was forbidden from 72 h before the first drug intake until
48 h after the last dosing. In addition to blood collections
for the main purposes of the study, urine was collected
before and at 0–2, 2–4, 4–6, 6–8, 8–12, 12–16 and 16–
24 h after caffeine intake. The urine containers were kept at
+4°C during the collection periods, and the participants were
instructed to void all urine during the collection periods in
the containers. Weight and pH of the urine collection were
recorded, and acidified samples (1 mL 6 M HCl) were stored
at −20°C until analysis.
Quantification of caffeine metabolites in urine
The caffeine metabolites 5-acetylamino-6-formylamino-3-
methyluracil (AFMU), 5-acetylamino-6-amino-3-methyluracil
(AAMU), 1-methylxanthine (1X) and 1-methylurate (1U)
were quantified with a fully validated LC-MS/MS method as
described earlier without modification [10]. The lower limit of
quantification was 100 ng/mL for all analytes except for
AAMU, where it was 200 ng/mL.
Statistical analysis
For each sampling interval, the molar urinary ratios
(AFMU+AAMU)/(AFMU+AAMU+1X+1U) were calcu-
lated as parameters of NAT2 activity [12]. As parameters of
XO activity, the molar urinary ratios (1U)/(1X+1U) were
calculated [13]. To obtain estimates of intra-individual and
inter-individual variability, linear mixed models were
established using maximum likelihood estimation based
on ln-transformed ratios of each collection period that took
“sequence”, “period”, and “comedication” as fixed effects,
and “volunteer (sequence)” as random effect into account.
The coefficient of variation of the multiplicative model
from the residual variance was considered as the intra-
individual variability, while the multiplicative coefficient of
variation obtained from the covariance of the random effect
“volunteer (sequence)” served as an estimate of the inter-
individual variability.
For the comparisons between sampling intervals, linear
mixed-effect models were fitted to assess the influence of
collection time on the variability between collection
periods. In these models, timing of collection intervals
was handled as a continuous variable and included as an
additional fixed effect. Statistical significance was accepted
for P ≤ 0.05. The intra-individual CVs were used to
estimate the sample size needed for a crossover interaction
study with the NAT2 and XO metrics under the assumption
that the ratio μtest/μreference is in the 0.95–1.05 interval with
90% confidence intervals between 0.80 and 1.25, a power
of 0.80 and P=0.05 [14]. SPSS 15.0.0 for windows (SPSS,
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Chicago, IL, USA), Excel 2003 (Microsoft, Redmond, WA,
USA), and SigmaPlot 10.0 (Systat Software, San Jose, CA,
USA) were used for statistical and graphical analysis.
Results
N-acetyltransferase 2
The urinary metabolite ratios which were used to assess
NAT2 activity were bimodally distributed starting with the
4–6 h collection period through the 16–24 h collection
period (Fig. 1). In the ANOVA-based mixed effect
modelling using ln-transformed metabolic ratios of these
collection intervals, neither the timing of the urine
collection (P=0.60) nor the period (P=0.28) or sequence
(P=0.38) was a significant factor of influence, while
comedication weakly influenced the overall model (P=
0.04). The overall intra-individual variability was 19.9%,
while inter-individual variability reached 67.0%. The
modelling of the individual collection periods from 4 to
24 h post-dose yielded intra-individual coefficients of
variation of the metabolic ratios between 10.5% (collection
interval 16–24 h post-dose) and 23.3% (collection interval
8–12 h post-dose), while inter-individual CVs ranged
between 36.5 and 74.8% (Table 1). No statistically
significant influence of comedication, period, or sequence
on the NAT2 ratios was observed in any model of the
individual collection periods.
Rapid and slow acetylators were well distinguished
(Figs. 1 and 2). Their respective overall mean metabolic
ratios in urine collected between 4 and 24 h after 150 mg
caffeine were 0.269 (CV, 18.7%) for rapid and 0.079 (CV,
31.9%) for slow acetylators. The acetylation phenotype did
not change between the periods (Fig. 2). It has to be noted,
however, that in three cases, ratios in isolated sampling
intervals were outside the range of their individual values
and their group means. Urine samples collected before the
caffeine test dose from two and five volunteers during
periods 1 and 2 respectively contained concentrations of
AFMU and/or AAMU which were above the quantification
limit. Since the intra-individual CV was 17.5% during the
4–6 h collection interval, a sample size of n=16 volunteers
appeared appropriate for crossover interaction studies
using this parameter (alpha=0.05, power 80%, true µtest/
µreference in the 0.95–1.05 range, “no effect” boundaries
0.8–1.25).
Xanthine oxidase
The ratios representing XO activity were unimodally
distributed. In the overall linear mixed effect model, time
was a significant factor of influence (P<0.00001) which led
to an increase in ratios by 14.5% from the 2–4 h collection
interval to the 16–24 h collection interval (Fig. 3). While
sequence (P=0.90) and comedication (P=0.36) did not
influence the ratios in the model, XO ratios during period 1
were 3.1% higher than during period 2 (P=0.024). In this
model, the inter-individual variability reached 8.2%, while
the global intra-individual coefficient of variation was 9.2%.
The arithmetic means and inter- and intra-individual coef-
ficients of variation for the individual collection periods are
shown in Table 1. The lowest intra-individual coefficient of
variation was 2.6%, observed in the collection interval 2–
4 h post-dose, while the highest was 18.2%, observed in the
collection interval 6–8 h after caffeine intake. The mean
interindividual coefficients of variation ranged between 6.5
and 10.3% (Table 1).
In the individual models for each collection period, no
statistically significant influences of the factors study period
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Fig. 1 Time courses of individual NAT2 metabolic ratios in 16
healthy non-smokers in the first (above) and second (below) period of
a crossover study. Time values represent the middle of collection
intervals
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(Fig. 4), sequence or comedication were observed. Before
dosing, the concentrations of 1U were above the quantifi-
cation limit in the urine of all volunteers, and concen-
trations of 1X were quantifiable in 13 and 14 urine samples
before the first and the second caffeine intake respectively.
Taking the same sampling interval and the same conditions
for sample size estimation as used for NAT2 into account,
the intra-individual variability of XO activity in the 4–
6 h collection interval of 3.6% would lead to a sample size
of n=6 for crossover interaction studies.
Discussion
Althoughmany investigations use urinary metabolite ratios for
the assessment of NAT2 and XO activities, to our knowledge,
the question of the appropriate urine sampling interval, which
is of importance for the validity and comparability of results,
has not yet been scrutinised. In the present investigation, a
short urine sampling interval of 2-h duration was sufficient if
more than 4 (NAT2) or 2 h (XO) had elapsed since the caffeine
test dose. While for NAT2 phenotyping, the exact choice of
collection time after that had no relevant influence on the
adequacy of the results, XO activity parameters increased
gradually with time. These results may facilitate future
research in this area and may help to establish the formal
correctness of earlier results.
For NAT2 phenotyping, three ratios based on urinary
caffeine metabolites have been proposed [15]. The ratio
used in the present investigation is an extension of the ratio
proposed by Tang and co-workers [12] which has been used
most frequently and is fairly well validated [10 and
references therein]. Since both AFMU and AAMU are
included in the formula we used, questions and problems
surrounding the deformylation of AFMU [10, 16] were
avoided.
For the assessment of XO activity, the ratios 1U/1X and
(1U)/(1X+1U) have been used and validated in combina-
tion with NAT2 and CYP1A2 assessments [17–21] and in
Table 1 Arithmetic means, inter-individual (CVinter) and intra-individual coefficients of variation (CVintra) for the urinary molar ratios for NAT2
and XO activity
NAT2 (all 16 participants) NAT2 rapid acetylators (n=7) NAT2 slow acetylators (n=9) Xanthine oxidase (n=16)
Sampling interval Mean CVinter CVintra Mean CVinter CVintra Mean CVinter CVintra Mean CVinter CVintra
Period 1: predose n.c. n.c. n.c. n.c. n.c. n.c. n.c. n.c. n.c. 0.820 3.6% 9.4%
Period 2: predose n.c. n.c. n.c. 0.812
Period 1: 0–2 h 0.112 49.1% 27.6% 0.148 9.1% 14.6% 0.077 29.1% 27.4% 0.520 7.9% 5.5%
Period 2: 0–2 h 0.119 0.165 0.065 0.534
Period 1: 2–4 h 0.134 82.2% 15.0% 0.235 5.0% 6.8% 0.059 20.5% 14.3% 0.541 6.5% 2.6%
Period 2: 2–4 h 0.150 0.277 0.065 0.549
Period 1: 4–6 h 0.161 74.8% 17.5% 0.267 7.4% 10.2% 0.078 24.1% 19.5% 0.556 6.9% 3.6%
Period 2: 4–6 h 0.163 0.279 0.074 0.571
Period 1: 6–8 h 0.152a 68.3% 20.0% 0.245a 10.6% 24.7% 0.071 18.3% 11.8% 0.600a 10.3% 18.2%
Period 2: 6–8 h 0.180 0.290 0.084 0.556a
Period 1: 8–12 h 0.167 36.5% 23.3% 0.267 2.2% 15.3% 0.089 14.1% 26.7% 0.604 8.7% 6.4%
Period 2: 8–12 h 0.186a 0.299 0.098a 0.580
Period 1: 12–16 h 0.169 36.6% 16.8% 0.274 22.5% 20.2% 0.087 19.6% 7.9% 0.611 7.4% 8.5%
Period 2: 12–16 h 0.166a 0.262a 0.082 0.583
Period 1: 16–24 h 0.160 66.6% 10.5% 0.257 9.5% 13.2% 0.076 15.5% 5.5% 0.642 7.8% 4.6%
Period 2: 16–24 h 0.165 0.274 0.081 0.624
n.c. Not calculated since analytes were below the quantification limit in more than 50% of participants
a Including one outlier; see text for details
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Fig. 2 Individual NAT2 activity quantified in urine collected 4–
6 h after dosing
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the framework of cocktail phenotyping studies [22–24]. No
direct comparison between the performance of the two
ratios has been published, and for both, some validation
issues have not yet been addressed. However, the latter
ratio is more easily interpreted (the more 1U is formed and
the more active XO is, the closer the values are to 1), and it
can still be calculated if all 1X has been converted to 1U.
Since 1X appears to be also a substrate for renal organic
anion transporters, inhibition of these transporters, e.g. by
probenecid, has an influence on the ratio [21, 25, 26].
Traditionally, most studies investigating NAT2 and XO
activities use 6-, 8-, or 12-h urine sampling intervals or spot
urine samples between 4 and 8 h after intake of the caffeine
test dose. While the latter may have advantages in large-
scale studies where urine collections over longer periods
may be impractical, our data suggest that, if urine collection
is carried out, it is sufficient to collect for 2 h at least
4 h after the dosing. For NAT2 phenotyping, the collection
interval 4–6 h after caffeine intake may be the best
compromise between accuracy of results (Figs. 1 and 2,
Table 1) and practicability for participants and investigators
(duration of caffeine abstinence and urine collection).
Longer collection periods may bear the risk that caffeine
abstinence is not observed. Interestingly, early publications
on NAT2 phenotyping denied the need for caffeine
abstinence [8, 27].
In the present investigation, we observed intra-individual
variabilities in NAT2 ratios between 10.5 and 23.3% from
4 h after dosing, and in XO ratios between 2.6 and 18.2%
from 2 h after dosing. Only a few published studies
quantify the intra-individual variability of NAT2 or XO.
The intra-individual variability is reported to be in a range
of 6 to 49% for NAT2 [8, 27] and about 5% for XO [18].
We could substantiate that the intra-individual variability
for both NAT2 and XO activity is low, at least under the
controlled conditions of a randomised clinical study. This
allows, e.g., the conduct of crossover interaction studies
with low numbers of participants. However, in three urine
collections 6 or more h after caffeine dosing, NAT2 ratios
were outside the range of the other individual values and in
the range of the opposite acetylator phenotype. For XO,
data in two volunteers, one in each period and direction,
deviated markedly from the mean starting with the 6–8 h
collection interval. These deviations had an impact on the
estimations of the intra-individual variabilities in the
respective collection periods. Since the first food intake
took place 6 h after caffeine dosing, it may be speculated
whether food intake had an influence, however, food was
standardised, and it remains elusive why outlying values
were only observed in one volunteer in each period. The
influences of comedication and period which were ob-
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served in the overall models for NAT2 and XO phenotyping
respectively were not observed in single collection period
models. Hence, these factors did not influence the estima-
tions of the variabilities for the individual collections, and
may have been observed by chance.
In predose urine samples of most volunteers, some
caffeine metabolites were quantified in low concentrations.
It may be speculated that the low quantification limits of
our analytical method enabled the quantification of these
metabolites which may have resulted from low-dose
contamination of food and beverages with methylxanthines.
Noncompliance seemed unlikely, since volunteers were
under observation the night before the phenotyping day,
and they were regularly questioned about adherence to
dietary restrictions.
Since for XO activity, both intra- and inter-individual
variability was lower than for NAT2 activity, and since
samples from 2–24 h after caffeine intake may be used for
XO activity assessment, the best choice for XO phenotyping
would be to use the same 4–6 h collection interval as used
for NAT2 phenotyping (Fig. 4).
In conclusion, the present investigation scrutinised the
influence of timing of urine collection intervals on NAT2
and XO activity parameters. Although the use of urine
collection 4–6 h after caffeine dosing appears to be the
optimum, most other later collection schedules yielded
valid results, if at least 4 h (2 h for XO phenotyping) had
elapsed. It has to be noted that the timing of the collection
interval influences the results of XO phenotyping. Hence,
XO activities quantified at different time intervals are not
comparable. In consideration of the low intra-individual
coefficients of variation, crossover studies which investi-
gate the interaction of a drug with NAT2 or XO using the
same ratios as used here may be carried out with as few as
16 and 6 participants respectively.
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